Amylyx’s new ALS drug has turned a profit for six months straight

Since its U.S. approval last fall, Relyvrio, the amyotrophic lateral sclerosis drug made by Amylyx Pharmaceuticals Inc., has turned its maker into a profitable company — and kept that streak going for six months straight.